WiCON | Pharma China (Web Edition)

ONLINE ENQUIRY

WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com

WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com

NHSA Seeks Public Input on 2025 Drug Reimbursement and Innovation List Reform ... The NHSA has released for public consultation a set of draft policy documents outlining the 2025 adjustment framework for the NRDL and a separate list for commercial heal...
(7/1/2025)

Accelerating US Oncology Drug Development Usin... (7/23/2025)

PharmaDJ's China Biopharma Tracker – June 202... (7/22/2025)

Analysing Key Trends In China's Patent-linkage... (7/12/2025)

China's Rising Biotechnology Sector: Friend or... (7/10/2025)

As Chinese-developed Drugs Draw U.S. Interest,... (7/8/2025)

FDA's Crackdown and China's Dealmaking: Warnin... (7/2/2025)

Medical Advances Soar With APAC's Clinical Tri... (7/2/2025)

Tracking the Crossroads of Policy, Innovation,... (7/1/2025)

BeOne Launches Phase III Trial Comparing Subcu... (7/1/2025)

China Launches Landmark Measures to Boost Inno... (7/1/2025)

Analyzing Key Trends in China's Patent-Linkage... (6/27/2025)

Fresh Antitrust Guidelines to Address Pharmace... (6/27/2025)

China-Singapore Nanovaccine Prevents Can... (7/23/2025) SAMR Orders Simcere to Reverse Unnotifie... (7/23/2025) DualityBio's DB‑1310 Earns FDA Fast‑Tr... (7/23/2025) Qilu Initiates Global Phase III Trial of... (7/23/2025) Kelun‑Biotech Launches Phase I Trial of... (7/23/2025) CDE Solicits Comments on Proposed Labeli... (7/22/2025) CDE Issues Q&A Guidance on Pharmaceutica... (7/22/2025) Livzon's Dual Inhibitor LZM‑012 Positiv... (7/22/2025) Cloudbreak Pharma Reports Positive Phase... (7/22/2025) Novatim Licenses Global Rights for Dual-... (7/22/2025) Simcere Zaiming Secures U.S. FDA Approva... (7/22/2025) AusperBio Cleared to Begin Phase III Tri... (7/22/2025) Leads Biolabs' Hong Kong IPO Draws HK$22... (7/22/2025) Suzhou Ribo Raises Over CNY 200M to Adva... (7/22/2025) Lannacheng Secures Over CNY 300M in Seri... (7/22/2025) Huadong Subsidiary Reports Strong Phase ... (7/22/2025) Innovent Secures IND for Oral GLP‑1 Ago... (7/22/2025) Chimigen Raises ~CNY 170M to Advance Can... (7/22/2025)

China Hospitals Prioritize Local Innovation, Digital He... China's Pharma Market Faces Mixed Performance in Q1 202... China's Retail Pharmacy Market Hits CNY 941.1B in 2024 ... NH's DB6: China's Consumer Healthcare Market Underperfo... China's Hospital Drug Market Shows Slight Growth in 202...

Chimigen Raises ~CNY 170M to Advance Cancer and HepB Va... Lannacheng Secures Over CNY 300M in Series C+ to Advanc... Suzhou Ribo Raises Over CNY 200M to Advance siRNA Thera... Leads Biolabs' Hong Kong IPO Draws HK$220B in Overwhelm... Novatim Licenses Global Rights for Dual-Target CAR-T Th...

CDE Issues Q&A Guidance on Pharmaceutical Similarity St... CDE Solicits Comments on Proposed Labeling Update for P... China Issues New Draft Guidelines for Pharmaceutical De... China Unveils New Clinical Trial Guidelines for Antibac... China Seeks Comments on 96th Batch of Reference Formula...

China Launches 11th Round of VBP, Covering 55 Medicines... China Releases 2nd Batch of Clinical Guidelines for Rar... China 2024 Healthcare Insurance Report: Milestones in C... China Issues 2nd Batch of Rare Disease Clinical Guideli... China's NHSA Unveils 2025 Drug Directory Revisions and ...

SAMR Orders Simcere to Reverse Unnotified Merger Over C... U.S. Lawmakers Raise Fresh Alarm Over GenScript's China... Record China Pharma Monopoly Fine Sends Strong Deterren... Conjupro Files USPTO Challenge on Ascletis' U.S. Patent... China's Draft National Medical Security Law: Seven Key ...

China Struggles to Maintain Grip on India's Bulk Drug M... API China 2025 Ends with High Attendance and Global Ind... FDA Issues Warning Letters to Two Chinese API Manufactu... Implications of China's Growing Influence in Global Pha... FDA Issues Warning to Tianjin Darentang for Manufacturi...

Kelun‑Biotech Launches Phase I Trial of SKB107 in Chin... Qilu Initiates Global Phase III Trial of QLS31905 for P... DualityBio's DB‑1310 Earns FDA Fast‑Track for EGFR‑M... China-Singapore Nanovaccine Prevents Cancer Recurrence ... Innovent Secures IND for Oral GLP‑1 Agonist IBI3032 as...

BioAtla and BeiGene Revise Global Deal for Novel Condit... Pfizer to Absorb Mylan, Creating Global Generic Powerho... PhRMA Calls for Trade Deals That Force Countries to Pay... IQVIA: Global Pharma to Grow Slower in the Next Five Ye... Pfizer and GSK Announce JV to Create a Global Consumer ...

Recent Executive Moves Astellas Pharma Executive Sentenced to 3½ Years in Chi... Recent Official and Executive Moves Recent Official and Executive Moves Recent Executive Moves

China Introduces Plan for Pudong New Area's Pilot Compr... Upcoming Event: 2023 Pharma CI USA Conference & Exhibit... Upcoming Event: 15th Annual Pharma Market Research Conf... Upcoming Event: 6th International Conference on Emergin... Upcoming Event: PHARM Connect Congress

Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...

WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...

2023 Order Form + Product Descripti... WiCON Publishes the China Pharmaceu... WiCON Publishes the China Pharmaceu... WiCON Publishes the China Pharmaceu... WiCON Publishes the China Pharmaceu...